UK unveils “real difference” bioscience industry strategy
This article was originally published in Clinica
A £180m ($281m) Biomedical Catalyst Fund is one of the headline initiatives of a new UK bioscience industry strategy. This and a raft of other groundbreaking, practical initiatives presented at the highest levels of industry and government promise to breathe new life into UK healthcare products manufacturing.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.